Kinetics and residues after intraperitoneal procaine penicillin G administration in lactating dairy cows

This paper describes the pharmacokinetic profile of procaine penicillin G after intraperitoneal (IP) administration in eight lactating dairy cows. Procaine pencillin G (PPG, 21 000 IU/kg) was deposited into the abdominal cavity of each cow following an incision in the right paralumbar fossa. Blood and milk samples were taken over the following 10 days, at which point the cows were euthanized. Plasma, milk, muscle, liver, and kidney penicillin concentrations were determined by HPLC, with a limit of quantification of 5 ng/mL for plasma and milk and 40 ng/g for tissue samples. A noncompartmental method was used to analyze plasma kinetics. The mean pharmacokinetic parameters (±SD) were: C _max, 5.5 ± 2.6 μg/mL; T _max, 0.75 ± 0.27 h; AUC _0-∞, 10.8 ± 4.9 μg·h/mL; MRT , 2.2 ± 0.9 h. All milk from treated cows contained detectable penicillin residues for a minimum of three milkings (31 h) and maximum of five milkings (52 h) after administration. Concentrations of penicillin in all muscle, liver, and kidney samples taken 10 days postadministration were below the limit of quantification. Necropsy examinations revealed foci of hemorrhage on the rumenal omentum of most cows but peritonitis was not observed. Systemic inflammation as determined by change in leukogram or plasma fibrinogen was noted in one cow. The results of this study demonstrate that IP PPG is absorbed and eliminated rapidly in lactating dairy cows.     

Milk residues and performance of lactating dairy cows administered high doses of monensin

Milk residues and performance were evaluated in lactating cows that were fed up to 10 times the recommended dose of monensin. Following an acclimatization period of 14 d, during which cows were fed a standard lactating cow total mixed ration containing 24 ppm monensin, 18 lactating Holstein dairy cows were grouped according to the level of feed intake and then randomly assigned within each group to 1 of 3 challenge rations delivering 72, 144, and 240 ppm monensin. Outcome measurements included individual cow daily feed intakes, daily milk production, body weights, and monensin residues in composite milk samples from each cow. There were no detectable monensin residues (< 0.005 microg/mL) in any of the milk samples collected. Lactating cows receiving a dose of 72 ppm monensin exhibited up to a 20% reduction in dry matter intake, and a 5% to 15% drop in milk production from the pre-challenge period. Cows receiving doses of 144 and 240 ppm monensin exhibited rapid decreases in feed intake of up to 50% by the 2nd d and milk production losses of up to 20% and 30%, respectively, within 4 d. Lactating cows receiving up to 4865 mg monensin per day had no detectable monensin residues (< 0.005 microg/mL) in any of the milk samples collected. Results of this study confirm that food products derived from lactating dairy cattle receiving monensin at recommended levels are safe for human consumption.     

Elimination kinetics of ceftiofur hydrochloride after intramammary administration in lactating dairy cows

OBJECTIVE: To determine the elimination kinetics of ceftiofur hydrochloride in milk after intramammary administration in lactating dairy cows. DESIGN: Prospective study. ANIMALS: 5 lactating dairy cows. PROCEDURE: After collection of baseline milk samples, 300 mg (6 mL) of ceftiofur was infused into the left front and right rear mammary gland quarters of each cow. Approximately 12 hours later, an additional 300 mg of ceftiofur was administered into the same mammary gland quarters after milking. Milk samples were collected from each mammary gland quarter every 12 hours for 10 days. Concentrations of ceftiofur and its metabolites in each milk sample were determined to assess the rate of ceftiofur elimination. RESULTS: Although there were considerable variations among mammary gland quarters and individual cows, ceftiofur concentrations in milk from all treated mammary gland quarters were less than the tolerance (0.1 microg/mL) set by the FDA by 168 hours (7 days) after the last intramammary administration of ceftiofur. No drug concentrations were detected in milk samples beyond this period. Ceftiofur was not detected in any milk samples from nontreated mammary gland quarters throughout the study. CONCLUSIONS AND CLINICAL RELEVANCE: Ceftiofur administered by the intramammary route as an extra-label treatment for mastitis in dairy cows reaches concentrations in milk greater than the tolerance set by the FDA. Results indicated that milk from treated mammary gland quarters should be discarded for a minimum of 7 days after intramammary administration of ceftiofur. Elimination of ceftiofur may be correlated with milk production, and cows producing smaller volumes of milk may have prolonged withdrawal times.     

Thiamphenicol pharmacokinetics in beef and dairy cattle

The pharmacokinetics of thiamphenicol were investigated in 10 calves and six lactating cows. It was found that this drug is rapidly absorbed (1 5 min) following intramuscular injection with an absorption rate constant and a bioavailability of 8.7 h^-1 and 84%, respectively. The drug appears to be widely distributed into various body fluids, yielding a volume of distribution (V_d(area)) of approximately 0.9 l/kg. The micro-rate constants indicated that the antibiotic rapidly diffuses into the peripheral compartment (k₁₂ > k₂₁). Elimination from plasma is relatively rapid, with a biological half-life of about 1.75 h. Thiamphenicol appears shortly in milk (15 min) after its intravenous administration, and gives milk to plasma concentration ratios greater than one between 4 and 12 h.     

Dexamethasone and flumethasone residues in milk of intramuscularly dosed cows

A field study was performed to assess the level of drug residues in milk after therapeutic application of highly potent synthetic glucocorticoids. Dexamethasone was tested either as a crystalline suspension or as a combination of sodium phosphate and phenylpropionate esters. Intramuscular injection of these preparations in lactating dairy cows (60 μg dexamethasone/kg body wt) yielded drug residues in milk of up to 8.4 ng/mL 12 h after treatment. These dexamethasone residues fell to below 1.0 ng/mL within 3 days after treatment. Intramuscular injection of an aqueous flumethasone preparation (13.5 μg/kg body wt) produced drug residues in milk in the range of 0.7-1.2 ng/mL 12 h after treatment, whereas flumethasone was below the detection limit of 0.23 ng/mL 2 days after administration. These results indicate that toxicologically significant residues may arise transiently in the milk during the first 2-3 days after intramuscular injection of synthetic glucocorticoids. Urine from the same animals contained 5- to 50-fold higher glucocorticoid concentrations than the corresponding milk samples. Thus, urine analysis appears to be an effective method to monitor the use of synthetic glucocorticoids in food producing animals.     

Licking induced changes to the pattern of moxidectin milk elimination after topical treatment in dairy cows

Pour-on administration of the macrocyclic lactones anti-parasitic compounds in beef and dairy cattle is now worldwide accepted. However, the information available on their milk excretion pattern, after topical administration is rather limited. Additionally, the cattle licking behaviour has been proven to affect the kinetics of these anti-parasitic compounds. The purpose of this study was to investigate the influence of the natural licking behaviour on the plasma and milk disposition of moxidectin (MXD), topically administered (500 μg/kg) in lactating dairy cows. Ten lactating Holstein dairy cows (705 kg body weight) were allocated into two experimental groups ( n  = 5). The licking was prevented during 5 days postadministration in animals in group I, and the remaining cows (group II) were allowed to lick freely. MXD concentrations profiles were measured in plasma and milk over 15 days posttreatment. The licking restriction period caused marked changes in MXD disposition kinetics both in plasma and milk. Both plasma and milk MXD concentrations (partial AUC 0–5 days) were significantly lower ( P  < 0.05) in licking-restricted cows. After the 5-day of restriction period, the animals were allowed to lick freely, which permitted the oral ingestion of MXD, situation clearly reflected both in plasma profile and milk excretion pattern. Despite the enhanced MXD milk concentrations measured in free-licking cows, drug concentrations did not reach the maximum MXD residues limit.     

The national milk safety program and drug residues in milk.

There are a number of factors that must be considered in any attempt to control animal drug residues in milk and milk products. Dairy herds vary greatly in number of cows. Milk from individual cows and farms is pooled, diluting drug residues that may be present in the milk from a single treated cow. Management techniques, including the handling, administration, and record keeping of animal drugs, vary greatly from one dairy to another. It is important that both veterinarians and nonveterinarians adhere to adequate milk discard times for animal drugs used to treat dairy animals. Observance of appropriate safeguards at the farm level, such as record keeping and clearly identifying treated animals, is critical for controlling and preventing the presence of illegal animal drug residues. Within the framework of the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, the FDA is working with state and other regulatory agencies and industry to better ensure the absence of illegal animal drug residues in milk and milk products. Preventive measures concentrate on minimizing the need to administer animal drugs to lactating cows, and diverting milk containing drug residues from the human food supply. Monitoring programs concentrate on screening milk and tracing violations to the individual producer. Minimizing illegal drug residues in milk and milk products requires close cooperation between farmers, veterinarians, the dairy industry, the pharmaceutical industry, and regulators.     

硫酸头孢喹肟子宫注入剂对泌乳期奶牛的安全性研究

为研究硫酸头孢喹肟子宫注入剂对泌乳期奶牛的安全性,试验选用24头泌乳期的健康中国荷斯坦奶牛,随机分为4组(每组6头),其中3个受试药物组(Ⅰ、Ⅱ、Ⅲ组)分别给奶牛子宫内注入不同剂量的硫酸头孢喹肟子宫注入剂,1个空白对照组(Ⅳ组),给奶牛子宫内注入一定剂量的灭菌生理盐水。给药2次,间隔72h。在给药第0天、末次给药日及停药第7天,观察记录试验奶牛的各项指标,包括体温(直肠温度)、脉搏、呼吸频率、血液生理和生化指标、精神状态等临床表现及日产奶量和乳汁体细胞数(SCC)等,并对其进行考查。结果表明,泌乳期奶牛按推荐方法使用受试药物硫酸头孢喹肟子宫注入剂较安全,临床可用于治疗泌乳期奶牛的子宫内膜炎。     

Safety Study on Cefquinome Sulfate Intrauterine Infusion for Lactating Cows

The aim of this experiment was to study the safety of cefquinome sulfate intrauterine infusion for lactating cows.24 healthy lactating Chinese Holstein cows were randomly divided into four groups(6 cows in each group).Cows in groups Ⅰ, Ⅱ and Ⅲ were respectively injected different doses of cefquinome sulfate intrauterine infusion in uterus, and cows in the blank control group(group Ⅳ) were injected the dose of sterilized saline water.The cows were injected with the tested drug in uterus for twice and the interval was 72 h.The indicators including body temperature(rectal temperature), pulse rate, respiratory rate, blood physiological and biochemical indexes, mental state, daily milk yield and somatic cell count(SCC) in milk were respectively observed and measured on the day of first administration, the day of final administration and the 7th day after final administration.The results showed that injecting lactating cows cefquinome sulfate intrauterine infusion to lactating cows as recommended dosage was safe.The drug could be used to treat endometritis of lactating cows in clinical practice.     

Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows

Phenylbutazone was administered intravenously (i.v.) to a group of four lactating cows at a dosage of 6 mg/kg body weight. Whole plasma, protein-free plasma and milk were analysed for phenylbutazone residues. Pharmacokinetic parameters of total and free phenylbutazone in plasma were calculated using a non compartmental method. In regards to whole plasma data, the mean volume of distribution at steady state ( V _ss), was 147 mL/kg body weight, with a mean (± SEM) terminal elimination half-life ( t _1/2) of 40 ± 6 h. The mean clearance ( Cl ) was 3 mL/h/kg body weight. The V _ss as determined from the protein-free plasma fraction was 50 021 mL/kg body weight. This larger V _ss of free phenylbutazone compared to total plasma phenylbutazone was attributed to a high degree of plasma protein binding, as well as the greater penetration of free phenylbutazone into tissues. The mean t _1/2 of free phenylbutazone was 39 ± 5 h. This similarity to the t _1/2 estimated from total plasma phenylbutazone data is attributed to an equilibrium between free and plasma phenylbutazone during the terminal elimination phase. Mean t _1/2 as determined from milk, applying a urinary excretion rate model, was 47 ± 4 h. Milk clearance of phenylbutazone was 0.009 mL/h/kg body weight, or about 0.34% of total body clearance. Furthermore, evidence suggests that phenylbutazone either binds to milk proteins, or is actively transported into milk, as its concentration in milk was greater than that predicted due to a simple partitioning from plasma into milk.     

Biliary secretion and enterohepatic recycling of fenbendazole metabolites in sheep

Fenbendazole (FBZ) was administered intraruminally at 5.0 mg/kg, containing a trace of [¹⁴C]-FBZ, to sheep fitted with a permanent bile duct cannula and the behaviour of FBZ and its metabolites examined in bile and plasma. Of the administered radiolabeled dose, 47% was secreted in bile of which 34% was accounted for as conjugated and 4% as unconjugated (free) metabolites. Hydroxylated oxfendazole (OH.OFZ) was the major biliary metabolite contributing 66%, and hydroxy-FBZ (OH.FBZ) 27%, of the total metabolites characterized. Small amounts of OFZ and hydroxy FBZ sulphone (OH. FBZ.SO₂) were also present in bile. The rapid appearance of OH.OFZ in bile, even before maximum concentrations of OFZ occurred in plasma, indicated that sulphoxidation and hydroxylation was the major route of FBZ metabolism.
Following intraduodenal infusion of free biliary metabolites, FBZ and its metabolites rapidly appeared in bile indicating absorption from the small intestine. When conjugated metabolites were infused they continued to appear in bile for a further 15–20 h after cessation of infusion indicating that absorption of hydroxylated metabolites occurred largely after bacterial deconjugation in the large intestine. Approximately 40% of biliary metabolites were estimated to undergo enterohepatic reabsorption but they contributed minimally to the metabolite content in plasma. It is suggested that during the process of recycling, biliary metabolites make substantial contact with parasites in the mucosa of the small and large intestine thereby contributing to the anthelmintic activity of FBZ.     

复合酵母培养物对奶牛产奶性能、氮排放及血液生化指标的影响

为研究饲料中添加复合酵母培养物对奶牛产奶性能、氮排放及血液生化指标的影响,选取年龄、体重、产奶量及泌乳期相近(135±15) d的荷斯坦奶牛24头,随机分为4组,每个处理6个重复,对照组和3个试验组的复合酵母培养物添加量分别为精料浓度的0,0.8%,1.0%,1.2%,随精料饲喂,测定产奶量、乳成分、氮排放及血液生化指标,结果表明,1)试验2组日均产奶量显著高于对照组(P<0.05),各试验组分别比对照组提高8.48%,10.05%,8.97%。2)复合酵母培养物能显著提高乳脂和乳蛋白率(P<0.05),显著降低牛奶体细胞数(P<0.05),以试验2组最低。3)在氮排放量上,试验2组显著低于对照组(P<0.05),各试验组比对照组分别降低8.47%,12.01%,9.36%。4)在血液生化指标方面,复合酵母培养物能提高血清中总蛋白、球蛋白、血糖、胰岛素水平(P<0.05),降低尿素氮水平(P<0.05)。由此可见,本试验条件下,综合考虑产奶量、乳成分、氮排放及血液生化指标,复合酵母培养物的最佳添加量为精料浓度的1.0%。     

Pharmacokinetic parameters and milk concentrations of ketoprofen after administration as a single intravenous bolus dose to lactating goats

Six clinically normal lactating does were administered ketoprofen (2.2 mg/kg intravenously (i. v.)). Blood and milk samples were collected prior to and for 24 h after drug administration. Drug concentrations in serum and milk were determined by high performance liquid chromatography. Pharmacokinetic parameters from each goat were combined to obtain mean estimates (mean ± SD) of half-life of elimination ( t _½β) of 0.32 ± 0.14 h, systemic clearance ( Cl ) of 0.74 ± 0.12 L/kg· h, and volume of distribution at steady state ( V _ss) of 0.23 ± 0.051 L/kg. In milk, ketoprofen was unmeasurable by the method employed (level of detection 25 ng/mL) for all samples.     

日粮添加不同水平的奶牛专用霉菌毒素吸附剂对粪中双歧杆菌数量和乳中黄曲霉毒素含量的影响

奶牛饲料原料中霉菌毒素广泛存在,并严重地威胁着奶牛健康,影响着奶牛生产性能的发挥。本试验选择年龄、胎次、产奶量、泌乳天数相近的荷斯坦牛80头探讨日粮添加4种剂量（0、10、15、20g）的霉菌毒素吸附剂对奶牛粪便中双歧杆菌数量和原料奶中黄曲霉毒素残留量的影响。与对照组（添加霉菌毒素吸附剂0g）相比,试验组奶牛粪便中双歧杆菌的外排量明显降低,但各实验组之间差异不显著,仅有数值上的变化。同时,随着霉菌毒素吸附剂含量的增加,原料奶中体细胞数呈现下降的趋势。与试验前相比,原料奶中黄曲霉毒素含量显著降低（P〈0.05）,且随着添加剂量的增加其黄曲霉毒素残留量更少,但添加20g与15g间无明显变化。因此,本研究表明,随着日粮中霉菌毒素吸附剂添加量的增加,可有效降低原料奶中黄曲霉毒素的残留量,进而提高原料奶质量。     

Serum and milk concentrations of apramycin in lactating cows, ewes and goats

A 20% solution of apramycin was administered intravenously (j.v.) and intramuscularly (i.m.) to lactating cows with clinically normal and acutely inflamed udders, to lactating ewes with normal or subclinically infected, inflamed udders and i.v. to lactating goats with normal udders. The i.v. disposition kinetics of apramycin was very similar in cows, ewes and goats. The elimination half-life was approximately 2 h and the steady-state volume of distribution was 1.26–1.45 L/kg. The absorption rate of the drug from the i.m. injection site was rapid, the i.m. bioavailability was 60–70% and the mean elimination half-life was 265 min in cows and 145.5 min in ewes. The binding percentage of apramycin to serum protein was low (< 22.5%). Concentrations of apramycin in milk produced by clinically normal mammary glands of cows, ewes and goats were consistently lower than in serum; the kinetic value AUC _milk/ AUC _serum was < 0.32. Drug penetration into the milk from the acutely inflamed quarters of cows was extensive; mastitis milk C _max values were more than tenfold greater than the C _max in normal milk. On the other hand, the drug had limited access to the milk produced by subclinically infected inflamed half-udders of ewes.     

An overview of aflatoxin B1 biotransformation and aflatoxin M1 secretion in lactating dairy cows

Milk is considered a perfect natural food for humans and animals. However, aflatoxin B1 (AFB1) contaminating the feeds fed to lactating dairy cows can introduce aflatoxin M1 (AFM1), the main toxic metabolite of aflatoxins into the milk, consequently posing a risk to human health. As a result of AFM1 monitoring in raw milk worldwide, it is evident that high AFM1 concentrations exist in raw milk in many countries. Thus, the incidence of AFM1 in milk from dairy cows should not be underestimated. To further optimize the intervention strategies, it is necessary to better understand the metabolism of AFB1 and its biotransformation into AFM1 and the specific secretion pathways in lactating dairy cows. The metabolism of AFB1 and its biotransformation into AFM1 in lactating dairy cows are drawn in this review. Furthermore, recent data provide evidence that in the mammary tissue of lactating dairy cows, aflatoxins significantly increase the activity of a protein, ATP-binding cassette super-family G member 2 (ABCG2), an efflux transporter known to facilitate the excretion of various xenobiotics and veterinary drugs into milk. Further research should focus on identifying and understanding the factors that affect the expression of ABCG2 in the mammary gland of cows.     

奶牛专用脲酶抑制剂复合预混料提高奶牛产奶量效果的试验

通过32头健康泌乳奶牛进行饲喂奶牛专用脲酶抑制剂复合预混料的对比试验.结果表明,饲喂脲酶抑制剂复合预混料的试验组,泌乳奶牛平均日产标准乳22.81kg/头,对照组泌乳奶牛平均日产标准乳20.12kg/头,产奶量提高13.37%(P<0.05);校正体重后试验组比对照组提高产奶量14.41%,差异显著(P<0.05);提高饲料转化率13.43%,差异显著(P<0.05);提高经济效益13.68%,增收效益明显。     

Supplementation with Calcium Salts of Linoleic and trans-Octadecenoic Acids Improves Fertility of Lactating Dairy Cows

Objectives were to evaluate effects of feeding a calcium salt rich in linoleic and trans -octadecenoic acids (LTFA) on synthesis of prostaglandin F_2α based on its metabolite (PGFM), uterine involution and pregnancy rates in lactating dairy cows. Five hundred and eleven Holstein cows were blocked according to parity, body condition score and milk yield in the previous lactation. Primiparous and multiparous cows were randomly assigned to one of the two treatments consisting of calcium salt (2% diet dry matter) of either palm oil (PO) or LTFA from 25 days prepartum to 80 days of lactation. Cows were time-inseminated at 70 ± 3 days postpartum. Feeding LTFA tended (p = 0.08) to decrease the incidence of puerperal metritis (15.1% vs 8.8%). Primiparous cows supplemented with LTFA showed larger increase in plasma PGFM concentration at day 1 postpartum (17018 vs 6897 p m ). Pregnancy rate after first insemination tended (p = 0.07) to be greater at 27 days after insemination (37.9% vs 28.6%), and was greater (p = 0.05) at 41 days after insemination (35.5% vs 25.8%) for cows fed LTFA compared with PO. These results indicate that unsaturated fatty acids fed in a rumen inert form have the potential to modulate reproductive events and improve pregnancy rates in lactating dairy cows.     

Drug residues in milk after intrauterine injection of oxytetracycline, lincomycin-spectinomycin, and povidone-iodine in cows with metritis

A study was conducted to document the maximum retention times of antimicrobial residues in milk after their use in intrauterine treatment of metritis in lactating cows and to evaluate several risk factors hypothesized to influence the retention time of these drugs. Oxytetracycline (3 g), lincomycin-spectinomycin (2 g of one-third lincomycin and two-thirds spectinomycin), or povidone-iodine (6 g) were given to cows with metritis by intrauterine route. The Bacillus stearothermophilus var calidolactis disk assay was performed on each milk sample. Of the 61 cows treated with oxytetracycline, 30 had residues in their postinjection milk for variable periods (range, 12.5 to 44.0 hours; mean, 26.6 +/- 10.3). Of the 47 cows treated with lincomycin-spectinomycin, 17 had residues in their postinjection milk for various periods (range, 14.5 to 24 hours; mean, 19.5 +/- 8.9). Povidone-iodine was not detected in milk. Because a high number of cows (n = 61) were treated with oxytetracycline, only data from these cows were used in testing the influence of 3 factors (severity of metritis, time after parturition when cows with metritis were treated, and parity) on maximum retention of the drug in milk. Severity of metritis did not have a significant influence (P greater than or equal to 0.1) on the maximum retention time of the drug. The retention time decreased linearly with the increase of time after parturition when the cow with metritis was treated. First lactation cows had a significantly (P less than or equal to 0.01) shorter retention time than did older cows.     

Fate of etiproston, a synthetic analogue of PGF2α, in cows

The pharmacokinetics and metabolic fate of labelled compounds were investigated after intramuscular administration of ³H-radiolabelled etiproston to nine cows. Elimination was rapid ( t _1/2β= 2.8 h). Forty-eight h after administration 92.6% of the radioactivity had been eliminated, mainly via the urinary (66% at 48 h) and faecal routes (26% at 48 h). In comparison, little elimination in milk occurred (less than 0.034% dose/l by 24 h). Radioactivity at the injection site 48 h after administration was seen in one cow (< 4.68 × 10^-5% dose/g). No radioactivity was detected in the tissues. Urinary metabolites were purified and isolated using XAD-2 extraction and preparative HPLC in reverse and normal phases. The main urinary metabolite, identified by mass spectrometry, was the tetranor acid derivative in equilibrium with its lactone form.